TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital of Guangzhou Medical University

About this trial

Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.

Eligibility criteria

Qualifiers

patients with advanced lung tumor or other solid tumor where biopsy is obtainable

Life expectancy >12 weeks

Child-Pugh-Turcotte score <7

Adequate heart,lung,liver,kidney function

Disqualifiers

Had accepted gene therapy before;

Tumor size more than 25cm;

Severe virus infection such as HBV, HCV, HIV, et al

Known HIV positivity

Trial design

Treatments tested in this trial

  • TCR-T cells

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

Second Affiliated Hospital of Guangzhou Medical University

Lead sponsor

Tcell Immune (Guangzhou) Science and Technology Ltd.

Collaborator